Down 41%, Is Kohl’s a Buy?

Kohl's (NYSE: KSS) has fallen by an even bigger 41% during this span. Kohl's rebounded strongly last year, but it was facing easy comparisons due to the pandemic's effects on 2020 results. It expected sales to increase 2% to 3% and operating margin to contract to 7.2% to 7.5%. Read More...

Motley Fool

Why Medpace Stock Soared Today

Shares of Medpace Holdings (NASDAQ: MEDP) surged 37.7% on Tuesday after the clinical contract research organization (CRO) delivered strong third-quarter results and issued an optimistic financial forecast for the year ahead. Medpace’s revenue jumped 30% year over year to $383.7 million, easily outpacing Wall Street’s estimates of roughly $357 million. The healthcare company, which helps pharmaceutical, biotechnology, and medical device companies conduct clinical trials, also saw its backlog grow by 21% to $2.2 billion as of the end of September.

Read More

Add Comment

Click here to post a comment